Cevostamab
- Generic Name
- Cevostamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2249888-53-5
- Unique Ingredient Identifier
- P86BHN01VE
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05927571
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv-Yafo, Israel
🇮🇱Sheba Medical Center - PPDS, Ramat Gan, Israel
🇦🇺The Alfred Hospital, Prahan, Victoria, Australia
Cevostamab Following CAR T Cell Therapy for RRMM
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 30
- Registration Number
- NCT05801939
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇫🇷
IGR, Villejuif, France
🇦🇺Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05535244
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04910568
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT03275103
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.